Skip to main content

Post-Operative Nausea and Vomiting

4
Pipeline Programs
6
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
2
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Genentech
GenentechCA - Oceanside
1 program
1
granisetronPhase 41 trial
Active Trials
NCT00231478Completed171Est. Dec 2007
MSD
MSDIreland - Ballydine
1 program
1
Comparator: MK0517Phase 3
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
Comparator: MK0517Phase 31 trial
Active Trials
NCT00231777Completed216Est. Nov 2005
Acacia Pharma
Acacia PharmaUK - Cambridge
1 program
1
14C-APD421Phase 11 trial
Active Trials
NCT02881840Completed6Est. Aug 2016
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
Comparator: MK0517PHASE_3
Roche
RocheSTAVANGER NORWAY, Norway
1 program
granisetronPHASE_4

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Genentechgranisetron
Sharp TherapeuticsComparator: MK0517
Acacia Pharma14C-APD421

Clinical Trials (3)

Total enrollment: 393 patients across 3 trials

NCT00231478Genentechgranisetron

A Study of Kytril (Granisetron) in the Prevention of Post-Operative Nausea and Vomiting (PONV) in Pediatric Subjects Undergoing Tonsillectomy or Adenotonsillectomy

Start: Apr 2007Est. completion: Dec 2007171 patients
Phase 4Completed
NCT00231777Sharp TherapeuticsComparator: MK0517

A Study to Examine the Safety and Tolerability of MK0517 for the Prevention of Post-Operative Nausea and Vomiting (0517-015)

Start: Jul 2005Est. completion: Nov 2005216 patients
Phase 3Completed
NCT02881840Acacia Pharma14C-APD421

Mass-balance Study of [14C]-APD421 in Healthy Volunteers

Start: Aug 2016Est. completion: Aug 20166 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.